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Leucocytes are a major component of the tumour microenvironment. Recent studies have indicated that the infiltration and activity
of these host cells are regulated by the tumour to promote its survival and progression. Through the production of an array of growth
factors, proteases and angiogenic mediators, leucocytes in the tumour microenvironment promote tumour growth, angiogenesis and
metastasis.
British Journal of Cancer (2004) 90, 2053–2058. doi:10.1038/sj.bjc.6601705 www.bjcancer.com
Published online 30 March 2004
& 2004 Cancer Research UK
Keywords: Leucocyte; tumour; progression; metastasis; angiogenesis
                              
TUMOUR-ASSOCIATED LEUCOCYTES
The infiltration of leucocytes into solid tumours was remarked
upon more than 100 years ago when it was suggested that they had
a causal role in carcinogenesis. These infiltrates are now known to
contain myeloid cells (neutrophils, dendritic cells, macrophages,
eosinophils and mast cells) as well as lymphocytes. However,
controversy remains over the relationship between these host cells
and tumour progression. In the past, their presence has been
construed as evidence for a host response against the growing
tumour. This is because such immune functions were often
observed in transplantable tumour models that by their nature
represented a transplant that could elicit immune rejection despite
being placed in immunocompromised hosts. However, it is
becoming clear that tumours growing naturally are largely
recognized as self and lack strong foreign antigens. Instead, they
appear to have been selected to manipulate the host immune
system to prevent rejection (Dunn et al, 2002) and use this system
to facilitate their own growth and spread (Khong and Restifo,
2002). This lack of immune response has become particularly
evident with the study of tumours induced by the restricted
expression of oncogenes in transgenic mice where it has been
established that tumour-associated leucocytes are often active
participants in the neoplastic process. In addition, there is a
growing body of clinical data on a wide range of solid tumour
types that has correlated a high density of leucocytic infiltration
with poor outcome (Coussens and Werb, 2001, 2002). Further-
more, it has be recognised that cells containing DNA alterations
caused by viral or chemical carcinogens do not progress to become
cancerous until they are exposed to a second type of stimulus that
often includes chronic irritants or inflammatory agents (Coussens
and Werb, 2002). For example, an inflammatory response is
required to induce cancers in chickens infected with the potent
oncogenic Rous Sarcoma virus despite it carrying the v-src
oncogene that alone is competent to transform fibroblasts in
culture (Sieweke et al, 1989). This view of the role of leucocytes in
facilitating cancer progression has been further enhanced by the
realisation that many cancers are caused or promoted by infectious
or other agents that induce chronic inflammation (Coussens and
Werb, 2002).
Under normal physiological circumstances, leucocytes are re-
cruited in response to wounding, inflammatory or pathogenic
stimuli. They are attracted by the local synthesis of chemokines
(chemoattractive cytokines), cytokines and growth factors as well as
products of tissue breakdown. These are all part of a signalling
system that involves recognition of the pathological state, organisa-
tion of an appropriate cellular response and suppression of this
response once the situation is resolved. During cutaneous wound
healing, these processes require epithelial cell proliferation and
migration, angiogenesis and tissue remodelling (Nathan, 2002). In
tumours, it is thought that similar chemoattractive factors are also
responsible for the recruitment of leucocytes and that these cells play
roles comparable to those observed during wound healing. However,
because of the accumulation of intrinsic mutations the epithelial
cells have lost positional identity and consequently do not stop
growing and migrating on cue. Instead, they send out continuous
signals that recruit leucocytes to continue to support the tumor’s
development. This concept has led to the rubric that tumours are
‘wounds that never heal’ (Balkwill and Mantovani, 2001).
Several steps are crucial for a tumour to become metastatic.
Tumour cells need to be able to break out of their confining
basement membranes in order to enter the extracellular matrix
and circulation. These processes require the proteolytic breakdown
of basement membranes, changes in epithelial cell adhesion,
migration and the suppression of ankoisis. They are matched in
the surrounding stroma with angiogenesis as well as the frequent
recruitment of leucocytes. Angiogenesis, known to be the crucial
process for tumour progression by providing oxygen and nutrients
and removal of waste products, as well as, providing an expanding
endothelial surface for the tumour cells to enter the circulation,
also involves degradation of basement membranes followed by
migration of endothelial cells into the tumour stroma (Folkman,
2002). Recent studies have shown that the tumour-associated
leucocytes produce factors that promote all these steps associated
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will focus on the evidence that members of the myeloid lineage,
particularly macrophages, neutrophils and mast cells, can facilitate
tumour progression.
Macrophages
Macrophages derived from circulating monocytes represent a
major component of the infiltrated leucocytic population in the
tumour microenvironment. These cells have a wide range of
functions in immunity, during development and in tissue repair.
They can adopt a particular phenotype according to the demand
and produce many factors ranging from chemokines, cytokines,
and proteases, to angiogenic and growth factors. They therefore
appear to be the ‘jack-of all trades’ of the myeloid lineage. Of all
the cells of the myeloid lineage, the evidence is strongest in
support of a positive impact of macrophages on tumour
progression. For example, in greater than 80% of clinical studies,
an increase in tumour-associated macrophages (TAMs) density is
correlated with poor prognosis, with less than 10% of studies
showing the converse (Bingle et al, 2002). Similarly, overexpres-
sion of macrophage chemoattractants within tumours has also
been shown to correlate with poor prognosis (Leek and Harris,
2002). One such example is colony stimulating factor-1 (CSF-1 or-
macrophage CSF), a macrophage growth factor as well as a potent
macrophage chemoattractant (Lin et al, 2002). Overexpression of
CSF-1 correlates with poor prognosis in human breast, ovarian
endometrial and prostatic carcinomas (Kacinski, 1997). In breast
cancers, this overexpression correlates with a strong leucocytic
infiltration in over 95% of cases (Scholl et al, 1994). Similarly, the
CC chemokine ligand 2 CCL2/MCP-1 (MCP¼monocyte chemoat-
tractant protein 1) has been identified as a major chemokine for
macrophages recruitment in several human tumours, including the
bladder (Amann et al, 1998), cervix (Riethdorf et al, 1996), ovary
(Negus et al, 1995), lung (Arenberg et al, 2000) and breast
(Valkovic et al, 1998; Ueno et al, 2000). The level of CCL2/MCP-1
expression is correlated with the increased infiltration of macro-
phage (Ueno et al, 2000) and the grade of tumour (Amann et al,
1998; Valkovic et al, 1998). Although both CSF-1 and CCL-2 can be
targeted to the tumour cells themselves, the strong correlation of
overexpression of these macrophage chemoattractants with
macrophage recruitment and poor prognosis suggests that TAMs
can play a major role in the progression of tumours to metastasis.
Several experiments have supported the role of macrophages in
tumour progression. We have observed that in a Polyoma Middle
T antigen-induced mouse model of breast cancer (PyMT), an
increase of macrophage infiltration at the primary tumour site
occurred immediately before the onset of malignant transition
(Figure 1) (Lin et al, 2001). Using genetic approaches, we
demonstrated that depletion of CSF-1 in this model markedly
decreased the infiltration of macrophages at the tumor site and this
correlated with a significant delay of tumour progression to
metastasis. In contrast, overexpression of CSF-1 in the tumour
dramatically increased the macrophage density in the primary
tumour and this was correlated with an accelerated malignant
switch (Lin et al, 2001). Similarly, removal of CSF-1 from
transplanted tumours also resulted in an impairment of growth
with extensive necrosis and poor vascularisation, phenotypes that
could be reversed by treatment of the mice with CSF-1 (Nowicki
et al, 1996). These studies have provided strong evidence that
TAMs promote the tumour progression to malignancy. This
conclusion was enhanced by the observations that treatment of
mice that had been xenotransplanted with either a human colonic
or embryonic tumour with antisense oligonucleotides directed
against mouse CSF-1 reduced tumour growth and prolonged
survival. This was associated with a reduced serum concentration
of CSF-1 and a decreased TAM density. Since mouse CSF-1 does
not stimulate the human receptor, these data argue for the effects
of the CSF-1 antisense molecules to be mediated through the
reduction in TAMs (Aharinejad et al 2002).
The evidence from both clinical and experimental studies
supports the view that, in most cases, TAMs facilitate tumour
progression and metastasis. The mechanism(s) macrophages used
to promote tumour progression are still unknown; however, it has
been proposed that macrophages may promote tumour growth
and angiogenesis through the production of growth factors and
angiogenic inducers such as Epidermal Growth Factor (EGF),
vascular endothelial growth factor (VEGF), tumour necrosis factor
(TNFa) and Thymidine Phosphorylase (TP) (Xiong et al, 1998;
Leek and Harris, 2002). Macrophages also indirectly enhance blood
vessel formation by possessing a procoagulant activity through
fibrin deposition (Mantovani et al, 1992). In addition, many
macrophages produced factors, proteases and protease activators
such as transforming growth factor-b (TGFb), platelet-derived
growth factor, interleukin-6 (IL-6), urokinase plasminogen acti-
vator and Tissue-type Plasminogen Activator (t-PA) that may
cause degradation of extracellular matrix to facilitate the tumour
cell invasion and migration and induce angiogenesis (Egami et al,
2003; Eubank et al, 2003; Hildenbrand et al, 1995; Klimetzek and
Sorg, 1977). Moreover, TAMs contribute greatly to the growth of
the tumour by producing proangiogenic and tumour-stimulating
chemokines such as CCR2 ligands (Vicari and Caux, 2002).
Macrophages can display tumour cytoxicity and can potentially
present tumour antigens to induce specific immune reaction
against tumours. However, these cells are believed to have
primarily a protumour function since both tumours and TAMs
produce potent immunomodulating agents that suppress macro-
phage tumoricidal activity. Such tumour-produced molecules,
including IL-4, IL-6, IL-10, CSF-1, TGFb and prostaglandin E2
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Figure 1 Leucocytic infiltration promotes tumour progression to
malignancy. In a manner similar to wounded tissues, solid tumours induce
a local ‘inflammatory response’ by attracting leucocytes into its micro-
environment. Such an infiltration consists of multiple cell types of which
cells of the myeloid lineage are the major component. Leucocytes in such
‘inflammatory sites’ produce an array of growth and angiogenic factors,
proteases and mutagenic factors that promote tumour growth, invasion
and angiogenesis. However, different from its physiological counterpart
whose inflammation ceases when the wound has healed, tumour-induced
inflammation persists and eventually leads to tumour progression and
metastasis.
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contribute to the general immunosuppression of the host as well as
the antitumour activity of macrophages (Elgert et al, 1998; Mytar
et al, 2003). Although infiltration of macrophages is usually
correlated with poor outcome (Hamada et al, 2002), recent studies
have also shown that infiltrated macrophages may have an anti
tumour action in colorectal cancer (Nakayama et al, 2002; Noguchi
et al, 2003). These observations indicate that the microenviron-
ment of different type of tumours might alter the activities of
infiltrated leucocytes from tumour promotion to tumour rejection.
This has led to the idea of tumour-educated macrophages whose
functions are modified by the local cytokine/chemokine environ-
ment (Pollard, 2004). In most cases, this enhances tumour
development and directs the local immune system away for an
antitumour response (Mantovani et al, 2002).
Dendritic cells (DCs) also play an important role in both the
activation of antigen-specific immunity and the maintenance of
tolerance, providing a link between innate and adaptive immunity.
Several clinical studies have reported the presence of DC within
human tumours such as the stomach, colon, prostate, kidney,
thyroid, breast and melanoma (Tsujitani et al, 1990; Enk et al,
1997; Troy et al, 1998; Bell et al, 1999; Lespagnard et al, 1999;
Schwaab et al, 1999, 2001; Scarpino et al, 2000). However, the effect
of such an infiltration in tumour progression is still not clear.
Some of these studies have shown that the infiltration of DC was
associated with enhanced patient survival (lung), whereas others
showed that DC present in tumour either were minimally activated
(Tsujitani et al, 1990; Troy et al, 1998), had no correlation with
metastasis-free or overall survival of the patients (Lespagnard et al,
1999) or were converted to ‘silencers’ of antitumour immune
responses by tumour-produced factors (Enk et al, 1997). In
addition, studies have reported that patients with a variety of
cancers have impaired function of DCs, indicating a systemic effect
of the tumours on DCs (Almand et al, 2000). Moreover, recent
studies have suggested that, instead of initiating immune
responses against tumours, DC in the tumour microenvironment
may have the ability to turn off the responding T cells and induce
tolerance (Hackstein et al, 2001; Vicari and Caux, 2002). The
relationship between host DC, lymphocytes and tumour in the
process of ‘tumour escape’ from the host immune system has been
reviewed in detail recently and will not be discussed here (Khong
and Restifo, 2002; Hanahan et al, 2003). Nevertheless, the evidence
on balance suggests that tumours promote the suppression of these
potentially damaging cells while enhancing the trophic nature of
macrophages. The hope, however, is that therapeutic modulation
of this environment locally could result in TAMs that are
tumoricidal and that together with properly matured DCs would
present antigens to infiltrating T cells with the consequent
rejection of the tumour (Dranoff, 2004).
Mast cells
An infiltration of mast cells has been found in a variety of human
cancers, including non-small-cell lung cancer (Shijubo et al, 2003),
breast cancer (Kankkunen et al, 1997), colorectal cancer (Lachter
et al, 1995), basal cell carcinoma (Yamamoto et al, 1997) and
pulmonary adenocarcinoma (Imada et al, 2000). The accumulation
of mast cells has been associated with enhanced growth and
invasion of several human cancers (Ribatti et al, 2001). However,
there are other studies in colorectal cancer where their presence is
indicative of improved prognosis (Nielsen et al, 1999). Initial
studies using animal models have shown that increasing mast cell
density in tumour promoted tumour growth (Roche, 1985),
whereas reducing their number inhibited tumour growth and
angiogenesis (Starkey et al, 1988). The role of inflammatory mast
cells in tumour progression of squamous epithelial carcinogenesis
was also illustrated recently (Coussens et al, 1999). Furthermore,
Schwann cell tumours caused by inherited mutations in the NF1
gene do not form in mouse models unless the surrounding stromal
cells are at least heterozygous for the mutation. These tumours are
highly populated with mast cells and it seems likely that a
haploinsufficiency of NFI in these cells is the cause of the tumour
formation (Zhu et al, 2002).
The best known role that mast cells plays in tumour progression
is their ability to induce tumour angiogenesis (Hiromatsu and
Toda, 2003). Activated mast cells produce a variety of angiogenic
growth factors, including VEGF, basic fibroblast growth factor, IL-
8 and TNFa (Meininger and Zetter, 1992; Qu et al, 1995; Hiromatsu
and Toda, 2003). In addition, they can produce specific angiogenic
mediators including histamine and heparin, which can stimulate
endothelial cell proliferation and may contribute to the hyper-
permeable nature of newly formed microvessels during patholo-
gical angiogenesis (Ribatti et al, 2001), and a variety of proteases,
particularly MMP9, which are involved in angiogenesis. How
tumour cells regulate the infiltration and activation of mast cells is
still not fully understood. However, several types of tumours
produce stem cell factor that may have functions in mast cell
migration, proliferation and activation (Turner et al, 1992). In
addition to the promotion of angiogenesis, the activated mast cells
are a rich source of cytokines and chemokines such as IL-1, IL-3,
IL-4, IL-8, granulocyte–macrophage colony-stimulating factor,
TNFa, interferon-g (IFNg), CCL-2, Macrophage Inflammatory
Protein MIP-1a and b, many of which can contribute to the
tumour microenvironment by enhancing tumour cell growth and
invasion either directly or through intermediaries such as
macrophages (Burd et al, 1989; Selvan et al, 1994).
Neutrophils
The role of neutrophils in tumour progression is still controversial.
During immune responses, they are among the first cells to arrive
at sites of infection where they are highly bactericidal. They are
also involved in cell killing during graft rejection and thus they
might be considered as potential antitumour cells. However,
clinical studies have been contradictory. The presence of increased
numbers of tumour-infiltrating neutrophils was linked to poorer
outcome in patients with adenocarcinoma of the bronchioloalveo-
lar carcinoma subtype (Bellocq et al, 1998), whereas studies of
gastric carcinoma suggested that neutrophil infiltration correlated
with good prognosis (Caruso et al, 2002). It has been reported that
tumours prolong alveolar neutrophil survival through the produc-
tion of soluble factors (Wislez et al, 2001). Using transplantable
tumour models, studies have shown that tumour-associated
neutrophils were involved in tumour angiogenesis by the
production of proangiogenic factors such as VEGF and IL-8
(Schaider et al, 2003), proteases such as matrix metalloproteinases
(Shamamian et al, 2001) and elastases (Iwatsuki et al, 2000; Scapini
et al, 2002). In addition, studies using animal models have also
shown that neutrophils may contribute to genetic instability in
tumours (Haqqani et al, 2000).
Furthermore, neutrophil-recruiting cytokines such as GRO (IL-8
homologues) may also directly stimulate tumour proliferation in
melanoma (Haghnegahdar et al, 2000). Taken together, an
environment that recruits neutrophils might enhance angiogenesis,
promote tumour invasion and stimulate growth.
CONCLUSION
Solid tumours are not just composed of malignant cells, but are
complex microcosms of many cell types including a wide range of
haematopoietic cells. The evidence described above suggests that
cells of the myeloid lineages, particularly macrophages, mast cells
and neutrophils, on balance play an active role in enhancing
tumour progression and metastatic capacity. This is through their
ability to promote angiogenesis and tissue remodelling as well as
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wound healing or in response to an inflammatory stimulus, a
similar panoply of cells is recruited. Sentinel cells, particularly
macrophages and mast cells that send out chemotactic signals that
in the first wave, bringing in neutrophils and monocytes, initiate
this recruitment. These not only eliminate pathogens but also
effect tissue repair, a process that involves angiogenesis and an
induction of vascular permeability, tissue remodelling and the
migration and proliferation of epithelial cells. These events are
coordinated by a sophisticated and as yet, not understood
language of soluble mediators involving cytokines, chemokines
and growth factors.
Similarly, during development, myeloid cells, particularly
macrophages, play an important role in tissue formation and
their absence often results in attenuated poorly formed structures
in tissues as wide ranging as bone, skin and mammary gland
(Pollard, 2004). It would seem highly likely that tumours send out
signals similar to those found in normal physiology to recruit
myeloid cells and instruct them to perform similar tasks in tissue
remodelling. However, unlike their normal counterparts, the
epithelial tumour cells do not stop growing in response to
positional cues and continuously send out signals to demand help
from the invading myeloid cells.
The tumour microenvironment also educates those invading
cells to promote epithelial growth, viability, motility and invasion.
Thus, it is noticeable in many tumour types that there are dense
lymphocytic infiltration sites adjacent to areas of basement
membrane breakdown and tumour invasion (Figure 1). In our
studies of the PyMT oncoprotein-induced mammary cancers, these
sites marked the transition from nonmalignant to malignant
tumours, suggesting that they had a causal role in this process.
Furthermore, it appears in this model that macrophages are the
sentinel cells that recruit other myeloid cells. This was confirmed
by the ablation of macrophages that stopped the infiltration sites
from occurring and which resulted in an inhibition of metastatic
capacity (Lin et al, 2001; 2003). The challenge, therefore, will be to
define whether there are unique phenotypes of these tumour-
associated myeloid cells that can distinguish them from those
involved in immune or tissue repair responses that could be a
target for therapeutic agents. In addition, it will be important to
understand the cytokine network in the tumour microenvironment
that promotes tumour progression so that it can be tilted away
from eliciting tropic activities to one that enhances the detection of
the tumours as an aberrant state with the resultant suppression of
its development and perhaps immunological rejection of the
tumour.
Note added in proof
Ablation of macrophage recruitment in transplantable breast
cancers by a chemokine receptor antagonist significantly inhibited
tumour development (Robinson et al, 2003). Similarly, inhibition
of MMP9 production in tumour-associated macrophages by a
hypomorphic Ets-2 mutation also inhibited tumour development
in the PyMT mouse model of breast cancer (Man et al, 2003).
These data confirms the involvement of macrophages in tumour
development in mouse models.
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